 |
|
Treatment of Tardive DyskinesiaIII. Clinical Efficacy of a Dopamine Competing Agent, Methyldopa
Hajime Kazamatsuri, MD;
Ching-piao Chien, MD;
Jonathan O. Cole, MD
Arch Gen Psychiatry. 1972;27(6):824-827.
Abstract
Abnormal movements of tardive dyskinesia are presumed to result from hyperactivity or supersensitivity of dopaminergic neurones in the brain. Methyldopa (Aldomet) is known to affect dopaminergic systems either by competitive inhibition of dopa decarboxylase or by synaptic action of its metabolite as a false neurotransmitter. Dual action of methyldopa on the dopamine receptor can then be expected theoretically to result in a somewhat equivocal response, although it was our hope that the results would be more helpful than harmful to the patients. On these theoretical grounds, methyldopa was administered to nine schizophrenics with tardive dyskinesia at daily dosages up to 1,000 mg over six weeks. Methyldopa did not show any marked clinical effect in suppressing abnormal mouth movements, while it induced considerable decrease in blood pressure. Psychotic episodes presumably due to methyldopa were observed in two patients.
Author Affiliations
Boston
From Boston State Hospital. Dr. Kazamatsuri is currently at Teikyo University School of Medicine, Tokyo.
Footnotes
Accepted for publication Aug 11, 1972.
Reprint requests to Boston State Hospital, 591 Morton St, Boston 02124 (Dr. Chien).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Therapeutic Strategies Against Tardive Dyskinesia: Two Decades of Experience
Jeste and Jed Wyatt
Arch Gen Psychiatry 1982;39:803-816.
ABSTRACT
The Assessment of Tardive Dyskinesia
Gardos et al.
Arch Gen Psychiatry 1977;34:1206-1212.
ABSTRACT
Neurological Syndromes Associated With Antipsychotic Drug Use: A Special Report
FREEDMAN
Arch Gen Psychiatry 1973;28:463-467.
ABSTRACT
|
